PHDS CEO, Helen Tan, went to Shenzhen in July, 2021 as a group member of Biopharmaceutical Industry and Safeguarding People’s Health Research against New Development Pattern and visited: Sainuosheng(Shenzhen) Gene Industry Development Co., Shenzhen MGI Tech Co.,Ltd, Center For Drug Evaluation Daya Bay Center, NMPA, Center for Medical Device Evaluation Daya Bay Center and Shenzhen Institute for Drug Control, and attended on-the-spot investigations and seminars and discussions.

During this visit, the research group held symposiums at Center For Drug Evaluation Daya Bay Center, NMPA, Center for Medical Device Evaluation Daya Bay Center and Shenzhen Institute for Drug Control respectively. And Professor Mao Zhenbin, Level 1 Counsel of the Division of Science and Technology Cooperation of NMPA presided over these symposiums and Zhu Kejin, Deputy Secretary-General of the Institute of Public Economics introduced the research group’s purpose, significance, ke research direction & items, expected results and influence etc. Other important attendees include Huang Xiaolong and Chen Bin, Director and Deputy Director of the Center For Drug Control Daya Bay Cennter, NMPA, Xu Liang, Deputy Director of CMDE Daya Bay Center and other experts and scholars. And they expressed warm welcome and introduced about their institutes, work progress, and key directions & key points of future review and examination work. In Shenzhen Institute for Drug Control, the research group held a warm discussion with Lu Yi, Wang Tiejie, the Principle and Deputy Principle of the institute.

After the in-depth investigation, the research group understood relevant institutes’ operation and work progress, collected research data, gained a deeper insight of relevant research issues and touched on the cooperation intention, which laid a sound foundation for the research.